Cohance Lifesciences Limited

BSE: COHANCE543064ISIN INE03QK01018

Healthcare
Pharmaceuticals
BSE 500

Share price

₹450.20+10.05 (+2.28%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹748.95
52W low: ₹267.85
Off 52W high: -39.89%
1M return: +0.77%
3M return: +4.95%
6M return: -6.39%
1Y return: -39.31%
20D avg volume: 54,728
50 DMA: ₹452.14
200 DMA: ₹409.58

Key ratios Consolidated

Market cap: ₹17,225 Cr
Current price: ₹450.20
52W high / low: ₹748.95 / ₹267.85
Face value: ₹1.00
P/E: 294.29
P/B: 4.40
EPS (TTM): ₹1.53
Book value / share: ₹102.23
ROE: —
ROCE: 4.80%
Operating margin: —
Net margin: —
Debt / equity: 0.04
Net debt: ₹120.53 Cr
Interest cover: 6.56
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 154.3 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	422.26	619.12	544.55	555.57	549.31	402.02	307.15	257.72	230.69	252.93	219.82	231.05
	12.25	1.84	6.16	15.60	14.17	10.57	15.71	14.12	18.16	17.05	14.35	19.84
	434.51	617.28	550.71	571.17	563.48	412.59	322.86	271.84	248.85	269.98	234.16	250.90
	477.38	580.86	505.25	487.40	492.62	360.99	213.13	172.34	165.77	199.13	168.70	145.49
	158.68	138.96	196.50	191.60	178.33	70.24	67.04	47.08	38.30	71.42	63.53	51.16
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	132.96	128.99	118.68	126.72	133.32	89.08	63.29	51.87	45.62	39.39	32.83	28.58
	6.74	9.19	9.11	8.76	10.18	5.75	3.33	1.67	1.60	2.30	1.27	0.50
	49.54	51.23	46.94	44.02	45.14	26.78	20.35	16.96	13.40	17.25	12.75	11.89
	167.86	177.00	171.61	166.77	155.84	105.38	70.53	49.78	14.46	19.94	14.42	13.16
	-42.87	36.42	45.46	83.77	70.86	51.60	109.73	99.50	83.08	70.85	65.47	105.41
	0.00	-16.51	-4.86	0.00	-8.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	-42.87	19.91	40.60	83.77	62.76	51.60	109.73	99.50	83.08	70.85	65.47	105.41
	2.32	11.60	11.58	17.38	16.36	12.87	26.44	17.52	22.32	17.48	18.71	25.84
	-45.19	8.31	29.02	66.39	46.40	38.73	83.29	81.98	60.76	53.37	46.75	79.56
	-0.63	0.51	0.96	1.94	1.28	1.65	3.26	3.23	2.39	2.10	1.84	3.13
Key metrics
	13.41	80.33	96.65	136.55	118.08	84.13	133.41	118.13	98.08	90.40	79.49	117.80
	3.20%	13.00%	17.70%	24.60%	21.50%	20.90%	43.40%	45.80%	42.50%	35.70%	36.20%	51.00%
	-10.70%	1.30%	5.30%	11.90%	8.40%	9.60%	27.10%	31.80%	26.30%	21.10%	21.30%	34.40%
	—	0.60%	—	1.90%	—	2.20%	—	—	—	—	—	—
	-23.10%	54.00%	77.30%	115.60%	138.10%	58.90%	39.70%	11.50%	—	—	—	—
	-197.40%	-78.50%	-65.20%	-19.00%	-23.60%	-27.40%	78.20%	3.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20
Income statement
	2,142	2,269	1,198	1,051	1,340	1,320	1,010	833.79
	35.85	34.09	58.56	61.91	46.36	92.38	14.24	18.12
	2,174	2,303	1,256	1,113	1,387	1,413	1,024	851.91
	2,051	2,066	912.22	707.59	826.96	786.12	610.02	495.61
	685.74	705.39	222.66	265.88	430.08	459.46	310.31	240.24
	0.00	0.00	0.00	—	—	—	—	—
	507.35	507.71	249.56	135.92	110.51	100.48	76.23	73.72
	33.80	37.24	12.35	7.45	5.44	6.23	9.14	23.07
	191.73	187.33	77.49	54.60	47.73	39.10	31.64	23.86
	683.24	671.22	267.53	61.11	69.28	—	46.22	40.02
	122.78	236.51	343.92	405.67	559.73	626.48	413.94	356.30
	-21.37	-29.47	0.00	0.00	0.00	0.00	0.00	0.00
	101.41	207.04	343.92	405.67	559.73	626.48	413.94	356.30
	42.88	56.92	79.15	105.39	148.44	213.78	105.33	87.51
	58.53	150.12	264.77	300.28	411.29	453.81	362.34	317.00
	2.78	4.69	10.52	11.80	16.16	17.83	14.23	24.91
Key metrics
	326.94	431.61	433.76	467.72	612.90	671.81	454.72	403.23
	15.27%	19.00%	36.20%	44.50%	45.70%	50.90%	45.00%	48.40%
	2.73%	6.60%	22.10%	28.60%	30.70%	34.40%	35.90%	38.00%
	—	4.80%	13.40%	—	—	—	—	—
	41.24%	89.40%	13.90%	-21.60%	1.50%	30.80%	21.10%	—
	-76.63%	-43.30%	-11.80%	-27.00%	-9.40%	25.20%	14.30%	—
	—	148.44	132.45	—	—	—	—	—
	—	2.45	1.09	—	—	—	—	—
	—	0.04	0.04	—	—	—	—	—
	—	120.53	-7.27	—	—	—	—	—
	—	154.3	113.1	—	—	—	—	—
Balance sheet
	—	5,730	3,032	—	—	—	—	—
	—	1,796	853.28	—	—	—	—	—
	—	49.14	85.40	—	—	—	—	—
	—	681.01	284.44	—	—	—	—	—
	—	562.23	166.57	—	—	—	—	—
	—	217.17	111.47	—	—	—	—	—
	—	1,990	995.20	—	—	—	—	—
	—	284.58	80.21	—	—	—	—	—
	—	645.93	365.19	—	—	—	—	—
	—	169.67	78.13	—	—	—	—	—
	—	119.19	71.89	—	—	—	—	—
	—	50.48	6.24	—	—	—	—	—
	—	4,034	1,841	—	—	—	—	—
Cash flow
	—	368.32	288.16	—	—	—	—	—
	—	-254.57	-255.30	—	—	—	—	—
	—	-165.15	3.32	—	—	—	—	—
	—	219.88	155.71	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	359.89	567.55	481.58	497.79	483.58	330.17	275.39	236.06	222.09	243.52	212.83	224.62
	12.16	-0.79	6.12	26.30	13.10	6.63	15.18	13.43	17.95	16.87	13.97	14.20
	372.05	566.76	487.70	524.09	496.68	336.80	290.57	249.49	240.04	260.38	226.79	238.82
	369.84	493.81	417.41	403.37	417.54	280.48	175.97	148.81	152.65	189.33	157.29	138.25
	151.90	134.63	193.29	188.19	175.16	66.98	55.11	39.17	34.73	63.16	60.65	46.95
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	96.34	96.81	85.09	95.10	103.43	52.72	50.34	44.25	43.17	37.10	30.62	26.51
	2.12	5.17	5.25	5.24	6.80	2.30	2.60	1.47	1.60	2.29	1.27	0.50
	34.32	37.66	33.36	31.20	31.36	15.19	13.44	12.29	12.00	15.66	11.33	10.48
	126.49	142.78	136.78	133.45	129.96	79.64	62.45	44.79	13.73	19.07	13.57	12.58
	2.21	72.95	70.29	120.72	79.14	56.32	114.60	100.68	87.39	71.06	69.50	100.57
	0.00	-16.51	-4.86	0.00	-8.10	0.00	—	—	—	—	—	—
	2.21	56.44	65.43	120.72	71.04	56.32	114.60	100.68	87.39	71.06	69.50	100.57
	0.80	21.88	18.14	26.43	18.47	11.98	28.25	24.35	22.32	17.62	17.14	25.84
	1.41	34.56	47.29	94.29	52.57	44.34	86.35	76.33	65.08	53.43	52.36	74.73
	0.04	0.90	1.24	2.46	1.38	1.74	3.39	3.00	2.56	2.10	2.06	2.94
Key metrics
	38.65	99.27	104.04	157.16	109.20	73.81	130.64	114.44	100.99	89.01	82.10	111.55
	10.70%	17.50%	21.60%	31.60%	22.60%	22.40%	47.40%	48.50%	45.50%	36.60%	38.60%	49.70%
	0.40%	6.10%	9.80%	18.90%	10.90%	13.40%	31.40%	32.30%	29.30%	21.90%	24.60%	33.30%
	—	1.30%	—	2.80%	—	2.50%	—	—	—	—	—	—
	-25.60%	71.90%	74.90%	110.90%	117.70%	35.60%	29.40%	5.10%	—	—	—	—
	-97.30%	-22.10%	-45.20%	23.50%	-19.20%	-17.00%	64.90%	2.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20
Income statement
	1,907	2,030	1,094	1,025	1,330	1,320	1,010	833.79
	43.79	44.73	53.98	55.09	44.55	187.79	14.24	18.12
	1,951	2,075	1,147	1,080	1,375	1,508	1,024	851.91
	1,684	1,732	796.14	671.31	795.24	785.56	609.98	494.32
	668.01	691.27	212.51	248.38	421.36	459.46	310.31	240.24
	0.00	0.00	0.00	—	—	—	—	—
	373.34	380.43	198.30	126.88	100.84	100.48	76.23	73.72
	17.78	22.46	8.00	7.43	5.39	6.23	9.14	21.81
	136.54	133.58	57.20	48.79	42.84	39.10	31.64	23.86
	539.50	542.97	233.60	58.17	66.28	57.10	46.17	39.98
	266.17	343.10	351.35	408.77	579.39	722.45	413.98	357.59
	-21.37	-29.47	0.00	—	—	—	—	—
	244.80	313.63	351.35	408.77	579.39	722.45	413.98	357.59
	67.25	84.92	79.64	103.96	146.79	164.35	105.33	87.51
	177.55	228.71	271.71	304.82	432.60	558.10	308.65	270.08
	4.64	5.98	10.67	11.97	16.99	21.92	12.12	21.22
Key metrics
	399.12	469.67	416.55	464.99	627.62	767.78	454.76	403.26
	20.93%	23.10%	38.10%	45.40%	47.20%	58.20%	45.00%	48.40%
	9.31%	11.30%	24.80%	29.70%	32.50%	42.30%	30.60%	32.40%
	—	7.30%	15.10%	—	—	—	—	—
	43.89%	85.70%	6.70%	-22.90%	0.70%	30.80%	21.10%	—
	-31.60%	-15.80%	-10.90%	-29.50%	-22.50%	80.80%	14.30%	—
	—	221.33	162.13	—	—	—	—	—
	—	1.70	1.11	—	—	—	—	—
	—	0.02	0.03	—	—	—	—	—
	—	82.13	50.64	—	—	—	—	—
	—	165.6	108.6	—	—	—	—	—
Balance sheet
	—	5,113	2,588	—	—	—	—	—
	—	1,669	708.76	—	—	—	—	—
	—	13.11	19.36	—	—	—	—	—
	—	641.61	242.47	—	—	—	—	—
	—	540.13	154.12	—	—	—	—	—
	—	194.84	97.17	—	—	—	—	—
	—	1,608	623.44	—	—	—	—	—
	—	260.15	71.03	—	—	—	—	—
	—	504.71	213.53	—	—	—	—	—
	—	95.24	70.00	—	—	—	—	—
	—	44.76	70.00	—	—	—	—	—
	—	50.48	0.00	—	—	—	—	—
	—	4,480	2,316	—	—	—	—	—
Cash flow
	—	389.57	301.03	—	—	—	—	—
	—	-204.29	-320.94	—	—	—	—	—
	—	-202.78	20.81	—	—	—	—	—
	—	168.24	138.90	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +15.14%
Sales CAGR 5Y: +15.00%
Profit CAGR 3Y: -19.14%
Profit CAGR 5Y: -5.82%
Sales YoY (TTM): +43.89%
Profit YoY (TTM): -31.60%

Consolidated

Sales CAGR 3Y: +19.17%
Sales CAGR 5Y: +17.57%
Profit CAGR 3Y: -28.53%
Profit CAGR 5Y: -16.16%
Sales YoY (TTM): +41.24%
Profit YoY (TTM): -76.63%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 57.49%

Quarter	September 2026	June 2026
Promoter %	57.49%	57.49%

Holder	Type	Holding	Previous	Change
BEHRYANDA LIMITED	Promoter	33.34%	33.34%	0.00%
JUSMIRAL HOLDINGS LIMITED	Promoter	24.15%	—	—
JASUB PROPERTY HOLDINGS LLP	Public	3.84%	3.84%	0.00%
SBI MNC FUND	Public	3.73%	3.33%	+0.40%
ICICI PRUDENTIAL HEALTHCARE FUND	Public	3.68%	—	—
DSP FLEXI CAP FUND	Public	2.90%	—	—
JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED	Public	2.51%	2.51%	0.00%
AMANSA HOLDINGS PRIVATE LIMITED	Public	2.18%	—	—
HDFC TRUSTEE COMPANY LIMITED - HDFC TAX SAVERFUND	Public	2.16%	—	—
SBI LIFE INSURANCE CO. LTD	Public	1.75%	1.75%	0.00%
INVESCO INDIA CONTRA FUND	Public	1.61%	1.69%	-0.08%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Cohance Lifesciences Limited	17,225	450.20	294.29	4.80%	+41.24% TTM	-76.63% TTM	-39.31%

Filings & corporate actions

Recent announcements

Revised Results Conference Call3 Nov 2026 · Company Update / Analyst / Investor Meet
Results Conference Call27 Oct 2026 · Company Update / Analyst / Investor Meet
Cohance Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve the Unaudited Financial ....26 Oct 2026 · Board Meeting / Board Meeting
General updates12 Oct 2026 · Company Update / General
Grant of Stock options to certain eligible employees of the Company9 Oct 2026 · Company Update / General
Appointment of Mr. Abhimanyu Ojha as Chief Financial Officer of the Company9 Oct 2026 · Company Update / Change in Management
Compliance Certificate under 74(5) of SEBI (DP) Regulations 20187 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
ESG Rating by Crisil ESG ratings & Analytics Limited6 Oct 2026 · Company Update / General
Closure of Trading Window28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
General update21 Sep 2026 · Company Update / General
General update18 Sep 2026 · Company Update / General
Scrutinizer`s report17 Sep 2026 · AGM/EGM / AGM
Proceedings of Annual General Meeting17 Sep 2026 · AGM/EGM / AGM
Investor Meet17 Sep 2026 · Company Update / Analyst / Investor Meet
Completion of USFDA Inspection5 Sep 2026 · Company Update / General
Press Release3 Sep 2026 · Company Update / Press Release / Media Release
Outcome of Committee Meeting3 Sep 2026 · Others / Outcome without intimation
Investors Meet27 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication27 Aug 2026 · Company Update / Newspaper Publication
BRSR26 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report 202626 Aug 2026 · Others / Reg. 34 (1) Annual Report
Notice of AGM 202626 Aug 2026 · AGM/EGM / AGM
Credit Rating13 Aug 2026 · Company Update / Credit Rating
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DSP Trustee Pvt Ltd12 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Earnings Call Transcript11 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication6 Aug 2026 · Company Update / Newspaper Publication
Con Call audio link5 Aug 2026 · Company Update / Analyst / Investor Meet
Completion of USFDA Inspection5 Aug 2026 · Company Update / General
Outcome of the Board Meeting5 Aug 2026 · Result / Financial Results
Outcome of the Board Meeting5 Aug 2026 · Board Meeting / Outcome of Board Meeting
Allotment of Equity Shares pursuant to exercise of Stock Options and grant of Stock Options to certain eligible employees of the Company23 Jul 2026 · Company Update / General
Results Conference Call23 Jul 2026 · Company Update / Analyst / Investor Meet
Cohance Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....23 Jul 2026 · Board Meeting / Board Meeting
Compliance Certificate under 74(5) of SEBI (DP) Regulations 20187 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Publication26 Jun 2026 · Company Update / Newspaper Publication
Clarification on Volume Movement24 Jun 2026 · Company Update / General
The Exchange has sought clarification from Cohance Lifesciences Ltd on June 24, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.24 Jun 2026 · Company Update / Clarification
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd19 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CSC Global Capital Markets (Singapore) Pte Ltd19 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Board meetings

6 Nov 2026 Board Meeting - Financial Results
5 Aug 2026 Board Meeting - Financial Results